These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 29127931)

  • 41. Vortioxetine for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
    Citrome L
    Int J Clin Pract; 2014 Jan; 68(1):60-82. PubMed ID: 24165478
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Antidepressants for the treatment of adults with major depressive disorder in the maintenance phase: a systematic review and network meta-analysis.
    Kishi T; Ikuta T; Sakuma K; Okuya M; Hatano M; Matsuda Y; Iwata N
    Mol Psychiatry; 2023 Jan; 28(1):402-409. PubMed ID: 36253442
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The safety and efficacy of vortioxetine for acute treatment of major depressive disorder: a systematic review and meta-analysis.
    Meeker AS; Herink MC; Haxby DG; Hartung DM
    Syst Rev; 2015 Mar; 4():21. PubMed ID: 25874839
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Vortioxetine versus placebo in major depressive disorder comorbid with social anxiety disorder.
    Liebowitz MR; Careri J; Blatt K; Draine A; Morita J; Moran M; Hanover R
    Depress Anxiety; 2017 Dec; 34(12):1164-1172. PubMed ID: 29166552
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Vilazodone for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
    Citrome L
    Int J Clin Pract; 2012 Apr; 66(4):356-68. PubMed ID: 22284853
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A Population Pharmacokinetic-Pharmacodynamic Meta-Analysis of Vortioxetine in Patients with Major Depressive Disorder.
    Naik H; Chan S; Vakilynejad M; Chen G; Loft H; Mahableshwarkar AR; Areberg J
    Basic Clin Pharmacol Toxicol; 2016 May; 118(5):344-55. PubMed ID: 26525043
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clinical benefits of vortioxetine 20 mg/day in patients with major depressive disorder.
    Christensen MC; McIntyre RS; Adair M; Florea I; Loft H; Fagiolini A
    CNS Spectr; 2023 Dec; 28(6):693-701. PubMed ID: 37070529
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Evidence for efficacy and tolerability of vilazodone in the treatment of major depressive disorder: a randomized, double-blind, placebo-controlled trial.
    Rickels K; Athanasiou M; Robinson DS; Gibertini M; Whalen H; Reed CR
    J Clin Psychiatry; 2009 Mar; 70(3):326-33. PubMed ID: 19284933
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Efficacy and safety of levomilnacipran sustained release in moderate to severe major depressive disorder: a randomized, double-blind, placebo-controlled, proof-of-concept study.
    Montgomery SA; Mansuy L; Ruth A; Bose A; Li H; Li D
    J Clin Psychiatry; 2013 Apr; 74(4):363-9. PubMed ID: 23656841
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Levomilnacipran extended-release: a review of its use in adult patients with major depressive disorder.
    Scott LJ
    CNS Drugs; 2014 Nov; 28(11):1071-82. PubMed ID: 25270036
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Vortioxetine: A multimodal antidepressant or another selective serotonin reuptake inhibitor?
    Keks NA; Hope J; Culhane C
    Australas Psychiatry; 2015 Jun; 23(3):210-3. PubMed ID: 25907797
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A randomized, double-blind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder.
    Jain R; Mahableshwarkar AR; Jacobsen PL; Chen Y; Thase ME
    Int J Neuropsychopharmacol; 2013 Mar; 16(2):313-21. PubMed ID: 22963932
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Efficacy of levomilnacipran extended-release in improving functional impairment associated with major depressive disorder: pooled analyses of five double-blind, placebo-controlled trials.
    Sambunaris A; Gommoll C; Chen C; Greenberg WM
    Int Clin Psychopharmacol; 2014 Jul; 29(4):197-205. PubMed ID: 24667487
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Vortioxetine : a review of efficacy, safety and tolerability with a focus on cognitive symptoms in major depressive disorder.
    Al-Sukhni M; Maruschak NA; McIntyre RS
    Expert Opin Drug Saf; 2015 Aug; 14(8):1291-304. PubMed ID: 26022537
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Vilazodone: in major depressive disorder.
    Frampton JE
    CNS Drugs; 2011 Jul; 25(7):615-27. PubMed ID: 21699273
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorder.
    Alvarez E; Perez V; Dragheim M; Loft H; Artigas F
    Int J Neuropsychopharmacol; 2012 Jun; 15(5):589-600. PubMed ID: 21767441
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Vortioxetine in patients with major depressive disorder and high levels of anxiety symptoms: An updated analysis of efficacy and tolerability.
    Adair M; Christensen MC; Florea I; Loft H; Fagiolini A
    J Affect Disord; 2023 May; 328():345-354. PubMed ID: 36708956
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Vortioxetine for Major Depressive Disorder in Adolescents: 12-Week Randomized, Placebo-Controlled, Fluoxetine-Referenced, Fixed-Dose Study.
    Findling RL; DelBello MP; Zuddas A; Emslie GJ; Ettrup A; Petersen ML; Schmidt SN; Rosen M
    J Am Acad Child Adolesc Psychiatry; 2022 Sep; 61(9):1106-1118.e2. PubMed ID: 35033635
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Vilazodone for the treatment of depression.
    Lindsey WT
    Ann Pharmacother; 2011 Jul; 45(7-8):946-53. PubMed ID: 21672888
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Vortioxetine (Lu AA21004) in the long-term open-label treatment of major depressive disorder.
    Baldwin DS; Hansen T; Florea I
    Curr Med Res Opin; 2012 Oct; 28(10):1717-24. PubMed ID: 22978748
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.